Rationale and Design of the First Double-Blind, Placebo-Controlled Trial with Allogeneic Adipose Tissue-Derived Stromal Cell Therapy in Patients with Ischemic Heart Failure: A Phase II Danish Multicentre Study.
Jens KastrupMorten SchouIda GustafssonOlav W NielsenRasmus MøgelvangKlaus F KofoedCharlotte KragelundJens Dahlgaard HoveAndreas Fabricius-BjerreMerete HeitmanMandana Haack-SørensenLisbeth Drozd LundEllen Mønsted JohansenAbbas Ali QayyumAnders Bruun MathiasenAnnette EkblondPublished in: Stem cells international (2017)
The aim of the present study is to demonstrate safety and the regenerative efficacy of the allogeneic CSCC_ASC product from healthy donors in a double-blind, placebo-controlled, multicentre study in patients with IHF.
Keyphrases
- double blind
- cell therapy
- phase ii
- placebo controlled
- clinical trial
- bone marrow
- stem cell transplantation
- heart failure
- adipose tissue
- phase iii
- mesenchymal stem cells
- stem cells
- study protocol
- open label
- phase ii study
- hematopoietic stem cell
- randomized controlled trial
- left ventricular
- high dose
- type diabetes
- low dose
- rectal cancer
- acute heart failure